Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185546 · ClinicalTrials.gov registry record · NA
Project 2 Cigarette and E-cigarette Nicotine Content and E-liquid Flavors
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 156
- Enrollment target
NCT03185546: Completed NA study, sponsored by Wake Forest University Health Sciences.
NCT03185546 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 156 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03185546, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 156 participants
- Enrollment target
Study Summary
Project 2 will evaluate the impact of very low nicotine content cigarettes, e-cigarette nicotine content, and e-cigarette flavoring on cigarettes smoked per day, nicotine exposure, puff topography, discomfort/dysfunction, other health-related behaviors, nicotine/tobacco dependence, biomarkers of tobacco exposure, intention to quit, compensatory smoking, other tobacco use, cardiovascular function, and perceived risk. Project 2 will also evaluate differences between conditions in compliance with product use and the ability to abstain from cigarette smoking when provided a financial incentive for abstinence from combusted tobacco. This is not a treatment program for smoking.
Primary Outcome
The average number of cigarettes (study and non-study, summed) smoked per day between the Week 10 and Week 12 visits (the end of the study).
Interventions
- OTHER NNC Spectrum Cigarette
- OTHER VLNC Spectrum Cigarette
- OTHER Moderate nicotine level e-liquid
- OTHER Low nicotine level e-liquid
- OTHER Tobacco Flavors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2018-08-06 |
| Est. Completion | 2020-03-13 |
| Phase | NA |
What the finished NCT03185546 record still lists
NCT03185546 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 5 interventions - of which NNC Spectrum Cigarette is the first listed.
NCT03185546 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03185546 about?
NCT03185546 is a clinical study titled "Project 2 Cigarette and E-cigarette Nicotine Content and E-liquid Flavors". Project 2 will evaluate the impact of very low nicotine content cigarettes, e-cigarette nicotine content, and e-cigarette flavoring on cigarettes smoked per day, nicotine exposure, puff topography, discomfort/dysfunction, other health-related behaviors, nicotine/tobacco dependence, biomarkers of tob...
What is the current status of trial NCT03185546?
This trial is currently completed. It is a NA study. The enrollment target is 156 participants. The study started on 2018-08-06. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT03185546?
The interventions under investigation include: NNC Spectrum Cigarette (OTHER), VLNC Spectrum Cigarette (OTHER), Moderate nicotine level e-liquid (OTHER), Low nicotine level e-liquid (OTHER), Tobacco Flavors (OTHER).
Who is sponsoring clinical trial NCT03185546?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03185546's enrollment target sits among peer trials
156 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI